While Abbott Labs will have relatively lower margins excluding AbbVie business, we expect overall margins to improve slightly.
The federal district and appellate courts both ruled against the government, AbbVie, which is based in North Chicago, Ill.
Medical device giant Abbott Laboratories, for example, recently announced it would jettison its laboratory-research-focused subsidiary into an entity called AbbVie.
FORBES: Why Spinoff Stocks Are Sizzling (And Should Stay Hot)
At AbbVie, the business is largely focused on proprietary pharmaceuticals such as Humira, which is expected to lose patent protection in 2016.
FORBES: A Less Acquisitive Abbott Labs Will Split in Two Come January
Post spin off, Abbott Labs is now left with generic drugs as research-based proprietary drugs like Humira have been retained by AbbVie.
And degrees or not, Gonzalez has proved himself sufficiently knowledgeable and politically adept to eventually become chief operating officer and to run AbbVie come January.
FORBES: Abbott Board Should Probe Confusion Over Gonzalez Credentials
He returned two years later and, late last year, was named to head the forthcoming spin off of the research-based pharma entity that will be called AbbVie.
FORBES: Abbott Board Should Probe Confusion Over Gonzalez Credentials
AbbVie will be even more reliant on the success of Humira in the first year of the split as its cholesterol drug franchise takes a hit from various patent expirations.
FORBES: A Less Acquisitive Abbott Labs Will Split in Two Come January
This is the first earnings result after the company spun off its proprietary pharmaceutical division as Abbvie Inc and all eyes will now be on the remaining divisions of the company.
AbbVie will likely pay the larger dividend, but with overseas markets accounting for a significant portion of operations, the company could incur a tax bill to repatriate profits to cover the distribution.
FORBES: Three Dividend-Paying Stocks To Buy For The Long Run
Just the same, the situation is unusual and, given that he will soon become AbbVie ceo, the Abbott board should take a closer look at his credentials and ensure everything is truly in order.
FORBES: Abbott Board Should Probe Confusion Over Gonzalez Credentials
Interferon-free regimens from Gilead and AbbVie Inc.
WSJ: Hepatitis C Dilemma: Treat Illness With Interferon Now or Wait?
AbbVie (No. 257) is the research-based pharmaceuticals business of Abbott Labs (No. 123) that started to publicly trade as an independent company in January of this year when the company officially separated into two public companies.
Among the largest underlying components of UPRO, in trading today AbbVie Inc. ( NYSE: ABBV) is down about 0.5%, ADT Corp ( NYSE: ADT) is down about 0.5%, and AES Corp. ( NYSE: AES) is lower by about 0.1%.
Among the largest underlying components of SDY, in trading today Pitney Bowes Inc ( NYSE: PBI) is down about 0.1%, AbbVie Inc. ( NYSE: ABBV) is down about 0.8%, and Consolidated Edison, Inc. ( NYSE: ED) is up by about 0.6%.
Among the largest underlying components of SDY, in trading today Pitney Bowes Inc ( NYSE: PBI) is up about 0.6%, AbbVie Inc. ( NYSE: ABBV) is up about 0.5%, and Consolidated Edison, Inc. ( NYSE: ED) is up by about 0.1%.
Among the largest underlying components of IXJ, in trading today AbbVie Inc. ( NYSE: ABBV) is up about 0.5%, Bristol-Myers Squibb Co. ( NYSE: BMY) is up about 1.2%, and UnitedHealth Group Inc ( NYSE: UNH) is up by about 2%.
Among the largest underlying components of SDY, in trading today Pitney Bowes Inc ( NYSE: PBI) is off about 0.1%, AbbVie Inc. ( NYSE: ABBV) is off about 0.4%, and Consolidated Edison, Inc. ( NYSE: ED) is lower by about 0.3%.
Among the largest underlying components of SDY, in trading today Pitney Bowes Inc ( NYSE: PBI) is up about 1%, AbbVie Inc. ( NYSE: ABBV) is up about 2.6%, and Consolidated Edison, Inc. ( NYSE: ED) is lower by about 0.2%.
The suburban Chicago drug and medical product giant is splitting into a medical products business that will be called AbbVie, and trade under a new ticker symbol, ABBV, while the other company will retain the Abbott name and largely be focused on medical products including devices, diagnostics and nutritional products.
FORBES: A Less Acquisitive Abbott Labs Will Split in Two Come January
应用推荐